Efficacy of Transarterial Chemolipiodolization with or without 3-Dimensional Conformal Radiotherapy for Huge HCC with Portal Tumor Thrombosis
Chan Ran You, M.D., Jeong Won Jang, M.D., Seok Hui Kang, M.D., Si Hyun Bae, M.D.,
Jong Young Choi, M.D., Seung Kew Yoon, M.D., Ihl Bhong Choi, M.D.1,
Dong Hoon Lee, M.D.2, Ho Jong Chun, M.D.2, Byung Gil Choi, M.D.2
Background/Aims The treatment efficacy for advanced hepatocellular carcinoma is poor. This study examined the efficacy and toxicity of 3-dimensional conformal radiotherapy (3D-CRT) in combination with transarterial chemolipiodolization (TACL) for a huge hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT). Methods: From March 2001 to November 2004, 49 patients with advanced HCC with PVTT (size>8 cm, modified UICC stage IVa) were enrolled in this retrospective study. Twenty two patients underwent more than 2 cycles of TACL (adriamycin 50 mg/m2, cisplatin 60 mg/m2, 5-fluorouracil 200 mg/m2 every 4-6 weeks) without 3D-CRT, while 27 patients underwent consecutive TACL with 3D-CRT (40-45 Gy for 4-5 weeks) that was started one week after the 1st TACL. The response was assessed by a computed tomography (CT) and the serum alpha-fetoprotein (AFP) level at 1-2 month intervals. Results: The objective response rates in the TACL group and TACL with 3D-CRT group were 18% and 48% at 3 months (P=0.051), and 10.5% and 42% at 6 months (P=0.024) respectively. The median survival time was 13 months and 13.5 months in TACL and TACL with 3D-CRT groups, respectively (P=0.502). The treatment response was better in the TACL with 3D-CRT group but there was no significant difference in survival between the two groups. Most toxicities in the two groups were mild, not exceeding grade 1 according to the WHO criteria. Conclusions: For patients with a huge HCC with PVTT, TACL with 3D-CRT achieved some meaningful clinical benefit. Prospective controlled trials will be needed to confirm the real benefit of TACL combined with 3D-CRT. (Korean J Hepatol 2007;13:378-386)
Multimodal treatment confers best overall survival results in patients with huge hepatocellular carcinoma: a systematic review and network meta-analysis Andrea Chierici, Mohamed El Zibawi, Guido Liddo, Rodolphe Anty, Stefano Granieri, Patrick Chevallier, Antonio Iannelli HPB.2024; 26(7): 895. CrossRef
Transcatheter arterial chemoembolisation followed by three-dimensional conformal radiotherapy versus transcatheter arterial chemoembolisation alone for primary hepatocellular carcinoma in adults Liming Lu, Jingchun Zeng, Zehuai Wen, Chunzhi Tang, Nenggui Xu Cochrane Database of Systematic Reviews.2019;[Epub] CrossRef
Advances in non-surgical management of primary liver cancer Xiao Chen World Journal of Gastroenterology.2014; 20(44): 16630. CrossRef
Multimodality Treatment Involving Radiotherapy for Advanced Liver-Confined Hepatocellular Carcinoma Hong In Yoon, Jinsil Seong Oncology.2014; 87(Suppl. 1): 90. CrossRef
Multimodality Management for Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma Chihwan Choi, Gi Hong Choi, Tae Hyun Kim, Masatoshi Tanaka, Mao-Bin Meng, Jinsil Seong Liver Cancer.2014; 3(3-4): 405. CrossRef
Radiotherapeutic Options for Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis Dong Soo Lee, Jinsil Seong Liver Cancer.2014; 3(1): 18. CrossRef
Hepatocellular carcinoma with portal vein tumor thrombosis: Improved treatment outcomes with external beam radiation therapy Ji‐Yoon Kim, Su‐Mi Chung, Byung‐Ock Choi, Chul‐Seung Kay Hepatology Research.2011; 41(9): 813. CrossRef
Successful Treatment of Stereotactic Body Radiation Therapy Combined with Transarterial Chemolipiodolization for Hepatocellular Carcinoma with Biliary Obstruction Chan-Kwon Park, Si-Hyun Bae, Hong-Jun Yang, Ho-Jong Chun, Il-Bong Choi, Jong-Young Choi, Seung-Kew Yoon The Korean Journal of Internal Medicine.2011; 26(1): 94. CrossRef
Treatment Algorithm for Intermediate and Advanced Stage Hepatocellular Carcinoma: Korea Jong Young Choi Oncology.2011; 81(s1): 141. CrossRef
Risk of HBV Reactivation According to Viral Status and Treatment Intensity in Patients with Hepatocellular Carcinoma Jeong Won Jang, Jung Hyun Kwon, Chan Ran You, Jin Dong Kim, Hyun Young Woo, Si Hyun Bae, Jong Young Choi, Seung Kew Yoon, Kyu Won Chung Antiviral Therapy.2011; 16(7): 969. CrossRef
Approach to radiation therapy in hepatocellular carcinoma Shumei Ma, Benzheng Jiao, Xin Liu, Heqing Yi, Dejuan Kong, Lin Gao, Guangtong Zhao, Yu Yang, Xiaodong Liu Cancer Treatment Reviews.2010; 36(2): 157. CrossRef
Practice guidelines for management of hepatocellular carcinoma 2009
The Korean Journal of Hepatology.2009; 15(3): 391. CrossRef
Challenge and Hope in Radiotherapy of Hepatocellular Carcinoma Jinsil Seong Yonsei Medical Journal.2009; 50(5): 601. CrossRef
